The study with the Corona vaccine the company Curevac is gone in the hot Phase: A Volunteer received at the University hospital of Tübingen, the first vaccination.
Then the young Person to stay 24 hours under observation – it will be monitored both in the Monitor as well as Doctors, said study leader Peter Kremsner of the German press Agency.
“In vaccination studies is, so far, never happened something Serious, but we want to make sure.”
Kremsner is expecting in two months, with the first results. “This will go pretty fix,” said the Director of the Institute for tropical medicine where the active ingredient is tested.
Already, reports have discovered because of the media hundreds of Volunteers. As soon as a letter is written with a call, it’ll probably be thousands of applications. For the University hospital of Tübingen, it was a home game.
For the study, 100 healthy participants between the ages of 18 and 60 years of age will be required. “If all goes well with the first Subject, come Monday, the next three on Wednesday, then four to eight and from then on, more and more,” said Kremsner.
You all would be observed in the connection, in the further course of the vaccination will increase the dose or even a second vaccination administered, if the first will be well tolerated.
The goal of the first Phase of the study was to learn about the compatibility and the immune system.
The tübingen-based company Curevac is working on so-called mRNA-vaccines. mRNA is a type of messenger molecule, in which the Instructions for the production of proteins is.
For your vaccine Curevac have provided researchers mRNA with the Instruction for a Protein of the Coronavirus Sars-CoV-2.
The human cells after vaccination of this Protein, which the body recognizes as foreign. He, however, makes antibodies and other immune cells.
Deutsche Presse-Agentur (dpa)
*The post “Uniklinik Tübingen: First Volunteer receives Corona vaccine from Curevac” is published by FitForFun. Contact with the executives here.